Evidence map›Paper›PMID 38398008›Full record

ArticleBiomedicines2024

Novel Brain-Penetrant, Small-Molecule Tubulin Destabilizers for the Treatment of Glioblastoma.

Lilian A Patrón, Helen Yeoman, Sydney Wilson, Nanyun Tang, Michael E Berens, Vijay Gokhale, Teri C Suzuki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lilian A PatrónReglagene, Inc., Tucson, AZ 85719, USA.
Helen YeomanReglagene, Inc., Tucson, AZ 85719, USA.
Sydney WilsonReglagene, Inc., Tucson, AZ 85719, USA.
Nanyun TangTranslational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
Michael E BerensTranslational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.ORCID 0000-0002-3382-6787
Vijay GokhaleReglagene, Inc., Tucson, AZ 85719, USA.
Teri C SuzukiReglagene, Inc., Tucson, AZ 85719, USA.
SilaGene (United States) · USTranslational Genomics Research Institute · US

Funding

Glioblastoma multiforme therapy via telomerase reverse transcriptase (hTERT) down-regulation. Molecular chaperones redirect quadruplex folding to reverse the effect of hTERT gene promoter mutations.R41NS110296 · NINDS · REGLAGENE, LLC · PI BERENS, MICHAEL E., HURLEY, LAURENCE H. · 2019 to 2019
$402k
NIH HHS R41NS11029NINDS NIH HHS R41 NS110296
6 · The paper itself

Abstract

Glioblastoma (GB) is the most lethal brain cancer in adults, with a 5-year survival rate of 5%. The standard of care for GB includes maximally safe surgical resection, radiation, and temozolomide (TMZ) therapy, but tumor recurrence is inevitable in most GB patients. Here, we describe the development of a blood-brain barrier (BBB)-penetrant tubulin destabilizer, RGN3067, for the treatment of GB. RGN3067 shows good oral bioavailability and achieves high concentrations in rodent brains after oral dosing (C

Indexed as

brain cancersglioblastomamicrotubulessmall moleculestubulin destabilizer

Identifiers

PMID38398008
PMCPMC10887108
OpenAlexW4391683428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.